Mortality in COVID-19 among women on hormone replacement therapy: a retrospective cohort study. (17th May 2022)

• Record Type: Journal Article
• Authors: Dambha-Miller, Hajira; Hinton, William; Wilcox, Christopher R; Joy, Mark; Feher, Michael; de Lusignan, Simon
• Is Part Of: Family practice. Volume 39:Number 6(2022)
• Page Start: 1049
• Page End: 1055
• Publication Date: 2022-05-17
• Subjects: combined oral contraceptive pill -- COVID-19 -- HRT -- mortality; Primary care (Medicine) -- Periodicals; Clinical medicine -- Periodicals; 616.005
• DOI: 10.1093/fampra/cmac041
• Languages: English
• ISSNs: 0263-2136

Abstract

Abstract: Background: Limited recent observational data have suggested that there may be a protective effect of oestrogen on the severity of COVID-19 disease. Our aim was to investigate the association between hormone replacement therapy (HRT) or combined oral contraceptive pill (COCP) use and the likelihood of death in women with COVID-19. Methods: We undertook a retrospective cohort study using routinely collected computerized medical records from the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) primary care database. We identified a cohort of 1, 863, 478 women over 18 years of age from 465 general practices in England. Mixed-effects logistic regression models were used to quantify the association between HRT or COCP use and all-cause mortality among women diagnosed with confirmed or suspected COVID-19 in unadjusted and adjusted models. Results: There were 5, 451 COVID-19 cases within the cohort. HRT was associated with a reduction in all-cause mortality in COVID-19 (adjusted OR 0.22, 95% CI 0.05 to 0.94). There were no reported events for all-cause mortality in women prescribed COCPs. This prevented further examination of the impact of COCP. Conclusions: We found that HRT prescription within 6 months of a recorded diagnosis of COVID-19 infection was associated with a reduction in all-cause mortality. Further work is needed in larger cohorts to examine the association of COCP in COVID-19, and to further investigate the hypothesis that oestrogens may contribute a protective effect against COVID-19 severity.